GB202007943D0 - Products & methods - Google Patents

Products & methods

Info

Publication number
GB202007943D0
GB202007943D0 GBGB2007943.0A GB202007943A GB202007943D0 GB 202007943 D0 GB202007943 D0 GB 202007943D0 GB 202007943 A GB202007943 A GB 202007943A GB 202007943 D0 GB202007943 D0 GB 202007943D0
Authority
GB
United Kingdom
Prior art keywords
products
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2007943.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SNIPR Biome ApS
Original Assignee
SNIPR Biome ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SNIPR Biome ApS filed Critical SNIPR Biome ApS
Priority to GBGB2007943.0A priority Critical patent/GB202007943D0/en
Publication of GB202007943D0 publication Critical patent/GB202007943D0/en
Priority to CA3171200A priority patent/CA3171200A1/en
Priority to EP21728227.6A priority patent/EP4158021A1/en
Priority to JP2022572491A priority patent/JP2023527819A/en
Priority to CN202180038118.1A priority patent/CN115552007A/en
Priority to PCT/EP2021/063954 priority patent/WO2021239758A1/en
Priority to FR2105486A priority patent/FR3110916A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
GBGB2007943.0A 2020-05-27 2020-05-27 Products & methods Ceased GB202007943D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB2007943.0A GB202007943D0 (en) 2020-05-27 2020-05-27 Products & methods
CA3171200A CA3171200A1 (en) 2020-05-27 2021-05-26 Multiplex crispr/cas system for modifying cell genomes
EP21728227.6A EP4158021A1 (en) 2020-05-27 2021-05-26 Multiplex crispr/cas system for modifying cell genomes
JP2022572491A JP2023527819A (en) 2020-05-27 2021-05-26 A multiplex CRISPR/Cas system for modifying the genome of cells
CN202180038118.1A CN115552007A (en) 2020-05-27 2021-05-26 Multiplex CRISPR/CAS systems for modifying the genome of a cell
PCT/EP2021/063954 WO2021239758A1 (en) 2020-05-27 2021-05-26 Multiplex crispr/cas system for modifying cell genomes
FR2105486A FR3110916A1 (en) 2020-05-27 2021-05-27 PRODUCTS & METHODS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2007943.0A GB202007943D0 (en) 2020-05-27 2020-05-27 Products & methods

Publications (1)

Publication Number Publication Date
GB202007943D0 true GB202007943D0 (en) 2020-07-08

Family

ID=71406263

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2007943.0A Ceased GB202007943D0 (en) 2020-05-27 2020-05-27 Products & methods

Country Status (7)

Country Link
EP (1) EP4158021A1 (en)
JP (1) JP2023527819A (en)
CN (1) CN115552007A (en)
CA (1) CA3171200A1 (en)
FR (1) FR3110916A1 (en)
GB (1) GB202007943D0 (en)
WO (1) WO2021239758A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024184403A2 (en) * 2023-03-06 2024-09-12 Snipr Biome Aps Targeting cells in stressed growing conditions

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4234696A3 (en) 2012-12-12 2023-09-06 The Broad Institute Inc. Crispr-cas component systems, methods and compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014124226A1 (en) 2013-02-07 2014-08-14 The Rockefeller University Sequence specific antimicrobials
WO2014191518A1 (en) * 2013-05-29 2014-12-04 Cellectis A method for producing precise dna cleavage using cas9 nickase activity
CA3218040A1 (en) * 2013-07-10 2015-01-15 President And Fellows Of Harvard College Orthogonal cas9 proteins for rna-guided gene regulation and editing
WO2015034872A2 (en) 2013-09-05 2015-03-12 Massachusetts Institute Of Technology Tuning microbial populations with programmable nucleases
US10584358B2 (en) 2013-10-30 2020-03-10 North Carolina State University Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri
NZ725006A (en) 2014-03-12 2019-11-29 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
CN106170550A (en) 2014-04-03 2016-11-30 麻省理工学院 For producing the method and composition guiding RNA
AU2015308910B2 (en) * 2014-08-27 2017-12-07 Caribou Biosciences, Inc. Methods for increasing Cas9-mediated engineering efficiency
JP2018515138A (en) 2015-05-06 2018-06-14 エスエヌアイピーアール・テクノロジーズ・リミテッドＳｎｉｐｒ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ Modification of microbial population and modification of microflora
GB2531454A (en) 2016-01-10 2016-04-20 Snipr Technologies Ltd Recombinogenic nucleic acid strands in situ
WO2016196361A1 (en) 2015-05-29 2016-12-08 North Carolina State University Methods for screening bacteria, archaea, algae, and yeast using crispr nucleic acids
KR102468240B1 (en) * 2015-06-15 2022-11-17 노쓰 캐롤라이나 스테이트 유니버시티 Methods and compositions for the efficient delivery of nucleic acid and RNA-based antimicrobial agents
WO2016205623A1 (en) 2015-06-17 2016-12-22 North Carolina State University Methods and compositions for genome editing in bacteria using crispr-cas9 systems
US20180200342A1 (en) 2015-07-13 2018-07-19 Institut Pasteur Improving sequence-specific antimicrobials by blocking dna repair
WO2017058751A1 (en) 2015-09-28 2017-04-06 North Carolina State University Methods and compositions for sequence specific antimicrobials
WO2017066497A2 (en) 2015-10-13 2017-04-20 Duke University Genome engineering with type i crispr systems in eukaryotic cells
US11542466B2 (en) 2015-12-22 2023-01-03 North Carolina State University Methods and compositions for delivery of CRISPR based antimicrobials
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
US20190323038A1 (en) * 2016-06-17 2019-10-24 Montana State Univesity Bidirectional targeting for genome editing
EP3532850A1 (en) 2016-10-28 2019-09-04 Massachusetts Institute Of Technology Synthetic bacteriophages and bacteriophage compositions
GB201710126D0 (en) * 2017-06-25 2017-08-09 Snipr Tech Ltd Vectors & Methods
CN111051510A (en) 2017-06-25 2020-04-21 斯尼普技术有限公司 Altering microbial populations and modifying microbial populations
US20190160120A1 (en) 2017-11-29 2019-05-30 Snipr Biome Aps Dna, methods etc
EP3740580A4 (en) 2018-01-19 2021-10-20 Duke University GENOME ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYONTS
WO2019152519A1 (en) * 2018-01-30 2019-08-08 Editas Medicine, Inc. Systems and methods for modulating chromosomal rearrangements
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
KR20210006344A (en) 2018-03-25 2021-01-18 에스엔아이피알 바이옴 에이피에스. Treatment and prevention of microbial infections
CA3099316A1 (en) * 2018-05-04 2019-11-07 Locus Biosciences, Inc. Methods and compositions for killing a target bacterium
WO2019227080A1 (en) 2018-05-25 2019-11-28 Locus Biosciences, Inc. Methods and compositions for killing a target bacterium
DK3802807T3 (en) 2018-06-05 2025-02-24 Lifeedit Therapeutics Inc RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE
US10711267B2 (en) 2018-10-01 2020-07-14 North Carolina State University Recombinant type I CRISPR-Cas system
US12264330B2 (en) 2018-10-01 2025-04-01 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for killing target cells
WO2020072250A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system and uses thereof for genome modification and alteration of expression
US12203123B2 (en) 2018-10-01 2025-01-21 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for screening for variant cells
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
GB201907733D0 (en) * 2019-05-31 2019-07-17 Governing Council Of The Univ Of Toronto Methods and compositions for multiplex gene editing
WO2021092254A1 (en) * 2019-11-06 2021-05-14 Locus Biosciences, Inc. Phage compositions comprising crispr-cas systems and methods of use thereof

Also Published As

Publication number Publication date
EP4158021A1 (en) 2023-04-05
WO2021239758A1 (en) 2021-12-02
CA3171200A1 (en) 2021-12-02
FR3110916A1 (en) 2021-12-03
JP2023527819A (en) 2023-06-30
CN115552007A (en) 2022-12-30

Similar Documents

Publication Publication Date Title
SG11202103781TA (en) Products, uses & methods
GB202006826D0 (en) Process
GB202005468D0 (en) Enzyme-media process
GB202005217D0 (en) Process
GB202007980D0 (en) Process
EP4162021A4 (en) Branched products
GB202002417D0 (en) Process
GB202202060D0 (en) Product
GB201908108D0 (en) Product
GB202002416D0 (en) Process
GB202007943D0 (en) Products & methods
GB201903318D0 (en) Product
GB201902992D0 (en) Product and method
CA195333S (en) Product packaging
PL3832540T3 (en) Product positioning method
GB202009069D0 (en) Process
GB201912021D0 (en) Methods, products & Uses relating thereto
GB2583732B (en) Methods and products
GB202003906D0 (en) Process
GB202001226D0 (en) Process
GB202206176D0 (en) Product
GB202104148D0 (en) Product
GB202101453D0 (en) Product
GB202016463D0 (en) Product
GB202001470D0 (en) Product

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)